Specify Company / Ticker to Get the Summary
Dividend History NRXP
Dividend Analytics NRXP
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–NRX Pharmaceuticals Inc
NRXPNRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801
Analytics
WallStreet Target Price
31.67 USDP/E Ratio
–Dividend Yield
–Financials NRXP
Results | 2019 | Dynamics |